|
1
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rampone B, Schiavone B, Martino A, Viviano
C and Confuorto G: Current management strategy of hepatocellular
carcinoma. World J Gastroenterol. 15:3210–3216. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rahbari NN, Mehrabi A, Mollberg NM, Müller
SA, Koch M, Büchler MW and Weitz J: Hepatocellular carcinoma:
current management and perspectives for the future. Ann Surg.
253:453–469. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Merle P and Mornex F: Medical therapies
for hepatocellular carcinoma. Cancer Radiother. 15:28–31. 2011.(In
French).
|
|
5
|
Kim E, Clark AL, Kiss A, Hahn JW,
Wesselschmidt R, Coscia CJ and Belcheva MM: Mu- and kappa-opioids
induce the differentiation of embryonic stem cells to neural
progenitors. J Biol Chem. 281:33749–33760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brillet K, da Conceição MM, Pattus F and
Pereira CA: Bioprocess parameters of cell growth and human mu
opioid receptor expression in recombinant Drosophila S2 cell
cultures in a bioreactor. Bioprocess Biosyst Eng. 28:291–293. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gein SV, Simonenko TA and Chereshnev VA:
Effect of beta-endorphin and DAGO, a selective agonist of mu-opioid
receptors, on the proliferative activity of lymphocytes. Dokl Biol
Sci. 391:289–291. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harburg GC, Hall FS, Harrist AV, Sora I,
Uhl GR and Eisch AJ: Knockout of the mu opioid receptor enhances
the survival of adult-generated hippocampal granule cell neurons.
Neuroscience. 144:77–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lennon FE, Mirzapoiazova T, Mambetsariev
B, Salgia R, Moss J and Singleton PA: Overexpression of the
μ-opioid receptor in human non-small cell lung cancer promotes Akt
and mTOR activation, tumor growth, and metastasis. Anesthesiology.
116:857–867. 2012.
|
|
10
|
Bortsov AV, Millikan RC, Belfer I,
Boortz-Marx RL, Arora H and McLean SA: μ-Opioid receptor gene A118G
polymorphism predicts survival in patients with breast cancer.
Anesthesiology. 116:896–902. 2012.
|
|
11
|
Yuen JW, So IY, Kam AY and Wong YH:
Regulation of STAT3 by mu-opioid receptors in human neuroblastoma
SH-SY5Y cells. Neuroreport. 15:1431–1435. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nylund G, Pettersson A, Bengtsson C,
Khorram-Manesh A, Nordgren S and Delbro DS: Functional expression
of mu-opioid receptors in the human colon cancer cell line, HT-29,
and their localization in human colon. Dig Dis Sci. 53:461–466.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang L and Karin M: Mammalian MAP kinase
signalling cascades. Nature. 410:37–40. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Molton SA, Todd DE and Cook SJ: Selective
activation of the c-Jun N-terminal kinase (JNK) pathway fails to
elicit Bax activation or apoptosis unless the phosphoinositide
3′-kinase (PI3K) pathway is inhibited. Oncogene. 22:4690–4701.
2003.
|
|
15
|
Dérijard B, Raingeaud J, Barrett T, Wu IH,
Han J, Ulevitch RJ and Davis RJ: Independent human MAP-kinase
signal transduction pathways defined by MEK and MKK isoforms.
Science. 267:682–685. 1995.
|
|
16
|
Kishimoto H, Nakagawa K, Watanabe T,
Kitagawa D, Momose H, Seo J, Nishitai G, Shimizu N, Ohata S,
Tanemura S, Asaka S, Goto T, Fukushi H, Yoshida H, Suzuki A, Sasaki
T, Wada T, Penninger JM, Nishina H and Katada T: Different
properties of SEK1 and MKK7 in dual phosphorylation of
stress-induced activated protein kinase SAPK/JNK in embryonic stem
cells. J Biol Chem. 278:16595–16601. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tournier C, Dong C, Turner TK, Jones SN,
Flavell RA and Davis RJ: MKK7 is an essential component of the JNK
signal transduction pathway activated by proinflammatory cytokines.
Genes Dev. 15:1419–1426. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Destrument A and Tournier C:
Physiological roles of MKK4 and MKK7: insights from animal models.
Biochim Biophys Acta. 1773:1349–1357. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iglesias M, Segura MF, Comella JX and
Olmos G: Mu-opioid receptor activation prevents apoptosis following
serum withdrawal in differentiated SH-SY5Y cells and cortical
neurons via phosphatidylinositol 3-kinase. Neuropharmacology.
44:482–492. 2003. View Article : Google Scholar
|
|
20
|
Maslov LN, Lasukova TV, Solenkova NV,
Lishmanov AIu, Bogomaz SA, Tam SV and Gross GJ: Participation of
K(ATP)-channels in cardioprotective effect of mu-opioid receptor
agonists in acute ischemia and reperfusion of the isolated heart.
Eksp Klin Farmakol. 64:23–27. 2001.(In Russian).
|
|
21
|
Gross GJ, Hsu A, Nithipatikom K, Bobrova I
and Bissessar E: Eribis peptide 94 reduces infarct size in rat
hearts via activation of centrally located μ opioid receptors. J
Cardiovasc Pharmacol. 59:194–197. 2012.PubMed/NCBI
|
|
22
|
Goldsmith JR, Uronis JM and Jobin C: Mu
opioid signaling protects against acute murine intestinal injury in
a manner involving Stat3 signaling. Am J Pathol. 179:673–683. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mathew B, Lennon FE, Siegler J,
Mirzapoiazova T, Mambetsariev N, Sammani S, Gerhold LM, LaRiviere
PJ, Chen CT, Garcia JG, Salgia R, Moss J and Singleton PA: The
novel role of the mu opioid receptor in lung cancer progression: a
laboratory investigation. Anesth Analg. 112:558–567. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Galeotti N and Ghelardini C: Regionally
selective activation and differential regulation of ERK, JNK and
p38 MAP kinase signalling pathway by protein kinase C in mood
modulation. Int J Neuropsychopharmacol. 20:1–13. 2011.PubMed/NCBI
|
|
25
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bermudez O, Pagès G and Gimond C: The
dual-specificity MAP kinase phosphatases: critical roles in
development and cancer. Am J Physiol Cell Physiol. 299:C189–C202.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang P, Han J and Hui L: MAPK signaling
in inflammation-associated cancer development. Protein Cell.
1:218–226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haeusgen W, Herdegen T and Waetzig V: The
bottleneck of JNK signaling: molecular and functional
characteristics of MKK4 and MKK7. Eur J Cell Biol. 90:536–544.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang B, Du J, Wang J, Tan G, Gao Z, Wang Z
and Wang L: Alpinetin suppresses proliferation of human hepatoma
cells by the activation of MKK7 and elevates sensitization to
cis-diammined dichloridoplatium. Oncol Rep. 27:1090–1096. 2012.
|
|
31
|
Giaroni C, Zanetti E, Vanti A, Canciani L,
Lecchini S and Frigo G: Sympathetic denervation-induced changes in
G protein expression in enteric neurons of the guinea pig colon.
Life Sci. 71:1961–1973. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen ZC, Shieh JP, Chung HH, Hung CH, Lin
HJ and Cheng JT: Activation of peripheral opioid μ-receptors in
blood vessel may lower blood pressure in spontaneously hypertensive
rats. Pharmacology. 87:257–264. 2011.
|
|
33
|
Wang Q and Traynor JR: Modulation of
μ-opioid receptor signaling by RGS19 in SH-SY5Y cells. Mol
Pharmacol. 83:512–520. 2013.
|
